PolyPid (NASDAQ:PYPD) Stock Rating Reaffirmed by HC Wainwright

PolyPid (NASDAQ:PYPD)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 295.48% from the company’s previous close.

PolyPid Stock Up 2.6 %

PYPD opened at $3.54 on Wednesday. PolyPid has a 1 year low of $2.95 and a 1 year high of $9.20. The firm has a 50 day moving average price of $3.52 and a 200 day moving average price of $4.08. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. The company has a market cap of $16.99 million, a PE ratio of -0.28 and a beta of 1.32.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.26. Sell-side analysts expect that PolyPid will post -4.39 earnings per share for the current year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.